Molina Healthcare Stock in Flux as Demand for Medicaid and Medicare Grows

MOH shares closed at $229.87 on July 3, 2026, trading in a $225.36 to $236.26 range that extends a sharp run: the stock is up roughly 27% over the past 30 days and nearly 67% over the past 90 days, well beyond the $226 level where shares had been consolidating in prior sessions . The move follows newly finalized 2025 risk-adjustment figures from the Centers for Medicare & Medicaid Services that pointed to higher-than-expected payments flowing to Molina, plus a fresh contract win in Illinois, where Molina Healthcare of Illinois was selected for a HealthChoice Illinois Medicaid managed care award starting January 1, 2027, for a four-and-a-half-year term with an extension option .

The rally sits on top of a broader Medicaid managed care margin squeeze that has pressured Molina alongside Centene, Elevance Health, and UnitedHealth since 2023, as state reimbursement rates lagged the actual medical cost trend tied to post-redetermination enrollment shifts . Molina felt this acutely last quarter: its medical care ratio (MCR) spiked to 94.6% in the fourth quarter of 2025, up from 90.2% a year earlier, contributing to a roughly 28% single-day share decline on a surprise quarterly loss and a weak initial 2026 outlook . Conditions have since stabilized, with first-quarter 2026 results showing a consolidated MCR of 91.1%, including 92% in Medicaid, both better than management had expected .

Even so, Molina reaffirmed rather than raised its full-year 2026 guidance, a more cautious posture than peers UnitedHealth and Elevance, which both lifted their outlooks after keeping medical spending in check in the first quarter, and it still expects Medicaid membership to decline about 6% this year as California, Illinois, New York, and Texas trim rolls . Management has flagged roughly $2.50 per share of guidance headwinds for 2026: about $1.50 tied to transitioning a new Florida Medicaid contract and about $1.00 from underperformance in traditional Medicare Advantage Part D plans the company plans to exit for 2027 . Guidance durability remains the focal point for investors, even as growing Medicaid and Medicare enrollment demand continues to underpin the longer-term managed care growth narrative.

Sell-side sentiment has firmed alongside the rally: JPMorgan raised its price target to $191 from $169 on June 8, 2026 while keeping a Neutral rating, and broader analyst fair-value estimates have moved toward the $259 to $260 range on improved confidence in Medicaid and Medicare Advantage margin recovery, though the group's consensus still leans toward Hold . The next checkpoint arrives with second-quarter 2026 results, due after market close on July 22, 2026, followed by a conference call the next morning, where investors will watch for confirmation that the medical cost trend improvement is holding .

Related Stocks

• MOH